Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex and Avastin for Non-Ischemic Central Retinal Vein Occlusion
NCT01295112Phase 3Completed
- Sponsor
- Texas Retina Associates
- Start
- May 2011
- Primary completion
- Oct 2015
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozurdex in central retinal vein occlusion (CRVO), sponsored by Texas Retina Associates. Primary endpoint: Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks. Started May 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT01295112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295112.